AAD2026:Late-BreakingNemolizumabDataDemonstrateClinicallyMeaningfulBenefitsforChildrenAged2to11WithModerate-to-SevereAtopicDermatitis
===2026/3/30 11:39:27===
ca.cohen@galderma.com
+41 21 642 76 43
=*=*=*=*=*=
当前为第10/10页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页
